<i>Burkholderia cepacia</i>Lower Respiratory Tract Infection Associated With Exposure to a Respiratory Therapist

Ramsey, Alan H.; Skonieczny, Patrice; Coolidge, Diane T.; Kurzynski, Terry A.; Proctor, Mary E.; Davis, Jeffrey P.

doi:10.1086/501928

Cited by 40 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…342,343 Many healthcareassociated outbreaks of Burkholderia infections associated with contaminated skin antiseptics, mouthwashes, ultrasound gels, medications, and medical devices have been described. [344][345][346][347][348][349][350][351][352][353][354][355][356][357][358][359][360][361][362] Other products that have become contaminated during use include nasal irrigation bottles contaminated with P. aeruginosa, 363,364 multiuse albuterol vials contaminated with B. cepacia, 348,357 acupuncture devices disinfected with glutaraldehyde contaminated with M. abscessus, 365 cosmetic surgical supplies contaminated with mycobacterial spp., and supplies used for liposuction. 366 Outbreaks of Achromobacter spp.…”

Section: Iiid2 Healthcare Sources: Water Surfaces Equipment Airmentioning

confidence: 99%

“…(2) Proper training of personnel responsible for reprocessing equipment is important, including demonstration of competency initially and then at least annually, as is consistent adherence to reprocessing guidelines. 421 (3) Single-dose medication vials are always preferred, due to the risk of contamination 349,357,422,423 (if multidose medication vials must be used, then the manufacturer's directions for handling, dispensing, and storing must be followed precisely to prevent contamination and the transmission of potential pathogens). (4) Tap water may be used for cleaning nebulizers and other respiratory therapy equipment, but sterile water or water processed by filtration (filter size of less than or equal to 0.2 microns) must be used in the final rinse because tap water and distilled water may be contaminated with CF pathogens.…”

Section: Ive2 Healthcare Facilities: Respiratory Therapy Nebulizementioning

confidence: 99%

See 1 more Smart Citation

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Saiman

Siegel

LiPuma

et al. 2014

Infect. Control Hosp. Epidemiol.

352

382

View full text Add to dashboard Cite

The 2013 Infection Prevention and Control (IP&C) Guideline for Cystic Fibrosis (CF) was commissioned by the CF Foundation as an update of the 2003 Infection Control Guideline for CF. During the past decade, new knowledge and new challenges provided the following rationale to develop updated IP&C strategies for this unique population:1. The need to integrate relevant recommendations from evidence-based guidelines published since 2003 into IP&C practices for CF. These included guidelines from the Centers for Disease Control and Prevention (CDC)/Healthcare Infection Control Practices Advisory Committee (HICPAC), the World Health Organization (WHO), and key professional societies, including the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). During the past decade, new evidence has led to a renewed emphasis on source containment of potential pathogens and the role played by the contaminated healthcare environment in the transmission of infectious agents. Furthermore, an increased understanding of the importance of the application of implementation science, monitoring adherence, and feedback principles has been shown to increase the effectiveness of IP&C guideline recommendations.2. Experience with emerging pathogens in the non-CF population has expanded our understanding of droplet transmission of respiratory pathogens and can inform IP&C strategies for CF. These pathogens include severe acute respiratory syndrome coronavirus and the 2009 influenza A H1N1. Lessons learned about preventing transmission of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative pathogens in non-CF patient populations also can inform IP&C strategies for CF.

show abstract

Section: Iiid2 Healthcare Sources: Water Surfaces Equipment Airmentioning

confidence: 99%

Section: Ive2 Healthcare Facilities: Respiratory Therapy Nebulizementioning

confidence: 99%

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Saiman

Siegel

LiPuma

et al. 2014

Infect. Control Hosp. Epidemiol.

352

382

View full text Add to dashboard Cite

show abstract

“…Aerosol-producing devices (e.g., nebulizers) may contain bacteria that can be aerosolized during use. In non-CF patients, health care-associated pneumonia has resulted from bacterial contamination of multidose medications vials due to aerosols generated by in-line and hand-held low-volume nebulizers (82,130,160,176; A. Crespo, P. Axelrod, K. St. John, K. Micklow, S. Alexander, F. Austan, P. Samuel, J. Arentzen, and A. Truant, Proc. 12th Annu.…”

Section: Care Of Respiratory Therapy Equipmentmentioning

confidence: 99%

Infection Control in Cystic Fibrosis

2004

View full text Add to dashboard Cite

Over the past 20 years there has been a greater interest in infection control in cystic fibrosis (CF) as patient-to-patient transmission of pathogens has been increasingly demonstrated in this unique patient population. The CF Foundation sponsored a consensus conference to craft recommendations for infection control practices for CF care providers. This review provides a summary of the literature addressing infection control in CF. Burkholderia cepacia complex, Pseudomonas aeruginosa, and Staphylococcus aureus have all been shown to spread between patients with CF. Standard precautions, transmission-based precautions including contact and droplet precautions, appropriate hand hygiene for health care workers, patients, and their families, and care of respiratory tract equipment to prevent the transmission of infectious agents serve as the foundations of infection control and prevent the acquisition of potential pathogens by patients with CF. The respiratory secretions of all CF patients potentially harbor clinically and epidemiologically important microorganisms, even if they have not yet been detected in cultures from the respiratory tract. CF patients should be educated to contain their secretions and maintain a distance of >3 ft from other CF patients to avoid the transmission of potential pathogens, even if culture results are unavailable or negative. To prevent the acquisition of pathogens from respiratory therapy equipment used in health care settings as well as in the home, such equipment should be cleaned and disinfected. It will be critical to measure the dissemination, implementation, and potential impact of these guidelines to monitor changes in practice and reduction in infections

show abstract

“…P. cepacia was firstly described by Burkholder in 1950 [26]. Ramsey et al [27] recorded that bacteria belonging to the genera Burkholderia are recognized as pathogenic in fish, however Kayis et al [28] reported that Burkholderia cepacia was isolated from rainbow trout fish farms in Turkey (2006-2008) but was not a fish pathogen.…”

Section: Introductionmentioning

confidence: 99%